Patents Assigned to ALMA THERAPEUTICS LTD.
-
Publication number: 20250065093Abstract: A drug delivery needle includes a body portion from which extends a penetration end that includes at least two sharp distal tips, the sharp distal tips being separated from each other by an arcuate trough that includes a cutting edge at least at a middle portion of the arcuate trough. At least the two sharp tips are made of a drug or include a drug therein or are coated with a drug. The drug is biodegradable.Type: ApplicationFiled: August 24, 2023Publication date: February 27, 2025Applicant: Alma Therapeutics Ltd.Inventor: Oz Cabiri
-
Publication number: 20220118234Abstract: An ingestible pill (1220, 1320) is provided including a medication-delivery device (1224, 1324), which is configured to deliver a medication (52) and includes a patch (1230, 1330) (a) having upper and lower surfaces (1232, 1234) that face in generally opposite directions, (b) disposed within an enteric coating (22) in a compressed shape (1242), (c) configured to assume an expanded shape (1244) after the enteric coating (22) dissolves. The patch (1230, 1330) includes a chamber (1270) defined by (a) a substantially water-impermeable and substantially gas-impermeable, elastic layer (1274) shaped so as to define at least one window (1276) therethrough, and (b) a liquid-permeable and substantially gas-impermeable wetting layer (1278), which entirely covers the at least one window (1276) and is sealed to the elastic layer (1274) around the at least one window (1276).Type: ApplicationFiled: August 13, 2019Publication date: April 21, 2022Applicant: Alma Therapeutics Ltd.Inventors: Yossi Gross, Oz Cabiri, Lital Ben-Shitrit
-
Patent number: 11197789Abstract: Embodiments are disclosed of a method of controlling timing and/or dosage of a transdermal drug patch. For example, a control device operative to move the patch to one or more of a plurality of operational relationships with a skin of a patient, including being fully engaged with the skin, partially engaged with the skin, and disengaged with the skin. The device may include a roller that peels a patch on and off the skin. Optionally a convention patch is used. In some embodiments a patch and/or an adaptor has a mobile zone and an immobile zone. In some embodiments, an active surface of the patch fully contacts the skin in an engaged state. For example the patch may be attached to the device on a passive portion thereof.Type: GrantFiled: August 17, 2018Date of Patent: December 14, 2021Assignee: Alma Therapeutics Ltd.Inventors: Oz Cabiri, Yossi Gross, Ran Hezkiahu
-
Patent number: 11147955Abstract: Embodiments are disclosed of a method of controlling timing and/or dosage of a transdermal drug patch. For example, a control device operative to move the patch to one or more of a plurality of operational relationships with a skin of a patient, including being fully engaged with the skin, partially engaged with the skin, and disengaged with the skin. The device may include a roller that peels a patch on and off the skin. Optionally a convention patch is used. In some embodiments a patch and/or an adaptor has a mobile zone and an immobile zone. In some embodiments, an active surface of the patch fully contacts the skin in an engaged state. For example the patch may be attached to the device on a passive portion thereof.Type: GrantFiled: February 18, 2016Date of Patent: October 19, 2021Assignee: Alma Therapeutics Ltd.Inventors: Yossi Gross, Oz Cabiri, Ran Hezkiahu
-
Patent number: 10980750Abstract: An ingestible pill is provided that includes an enteric coating and a medication-delivery device, which includes (a) a patch having upper and lower surfaces that face in generally opposite directions, and (b) needles. The patch is disposed within the enteric coating, folded so as to define one or more creases, which define respective inner and outer crease sides, wherein at least 50% of the needles are coupled to the patch along the inner crease sides. The patch is configured to assume, after the enteric coating dissolves, an expanded shape, in which the patch has an outer perimeter. Other embodiments are also described.Type: GrantFiled: June 8, 2020Date of Patent: April 20, 2021Assignee: Alma Therapeutics Ltd.Inventors: Yossi Gross, Oz Cabiri
-
Publication number: 20200297646Abstract: An ingestible pill is provided that includes an enteric coating and a medication-delivery device, which includes (a) a patch having upper and lower surfaces that face in generally opposite directions, and (b) needles. The patch is disposed within the enteric coating, folded so as to define one or more creases, which define respective inner and outer crease sides, wherein at least 50% of the needles are coupled to the patch along the inner crease sides. The patch is configured to assume, after the enteric coating dissolves, an expanded shape, in which the patch has an outer perimeter. Other embodiments are also described.Type: ApplicationFiled: June 8, 2020Publication date: September 24, 2020Applicant: Alma Therapeutics Ltd.Inventors: Yossi Gross, Oz Cabiri
-
Patent number: 10675248Abstract: An ingestible pill is provided that includes an enteric coating and a medication-delivery device, which includes (a) a patch having upper and lower surfaces that face in generally opposite directions, and (b) needles. The patch is disposed within the enteric coating, folded so as to define one or more creases, which define respective inner and outer crease sides, wherein at least 50% of the needles are coupled to the patch along the inner crease sides. The patch is configured to assume, after the enteric coating dissolves, an expanded shape, in which the patch has an outer perimeter. Other embodiments are also described.Type: GrantFiled: August 14, 2018Date of Patent: June 9, 2020Assignee: Alma Therapeutics Ltd.Inventors: Yossi Gross, Oz Cabiri
-
Patent number: 10004887Abstract: An assembly includes a patch including a substance adapted for transdermal delivery, and a driver operative to move the patch to one or more of a plurality of operational relationships with a skin of a patient, including being in full contact with the skin, partial contact with the skin, and no contact with the skin.Type: GrantFiled: February 18, 2015Date of Patent: June 26, 2018Assignee: ALMA THERAPEUTICS LTD.Inventors: Yossi Gross, Oz Cabiri